Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis (MS). Current management options for NOAB in MS have limited efficacy and considerable adverse
| Condition(s) | Neurogenic Bladder, Multiple Sclerosis, Overactive Bladder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis (MS). Current management options for NOAB in MS have limited efficacy and considerable adverse effects, which underscores the significance of this study and highlights the need for better, less invasive therapies. This novel study investigates brain therapeutic targets that could shift the focus of NOAB management in MS from a bladder-centric focus to brain restoration; specifically modulating the brain regions identified in the prior functional magnetic resonance imagining studies. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation |
| Who can participate | Inclusion Criteria: * Adult women (≥ 18 years of age) * Clinically stable MS defined as ExpandedDisability Status Score (EDSS) ≤ 7.5without exacerbation worsening in the preceding 6 months prior to study entry * Neurogenic Lower Urinary Tract Dysfunction symptoms ≥ 3 months with NBSS total ≥ 15 * Individuals with Montreal Cognitive Assessment (MoCA) score \>10 will be eligible * At least one bladder storage symptoms (e.g., urinary frequency, urinary urgency, nocturia with or without incontinence) indicated by OAB -AT≥ 8 * Individuals with active urinary tract infection (UTI) will be treated and will be enrolled after negative urinalysis Exclusion Criteria: * Pregnant/planning to become pregnant or nursing * Urodynamic findings of bladder outlet obstruction * Baclofen or other intrathecal p |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | The Methodist Hospital Research Institute |
| Locations | Houston, Texas, United States |
| Start date | 2023-10-30 |
| NCT ID | NCT06072703 |
| Official listing | https://clinicaltrials.gov/study/NCT06072703 |